Oral Psoriasis Treatments: When Results Peak and How Long They Last
Psoriasis treatments can take time to reach their full effect, and some areas of the body may respond more slowly than others. Understanding what researchers have observed so far may help people have more informed conversations with their dermatologist.
In a Dermatology Times Expert Perspectives video series, dermatologist Mark Lebwohl, MD, discussed several oral psoriasis medicines: icotrokinra (Icotyde; Johnson & Johnson), envudeucitinib (Alumis), and zasocitinib (Takeda). He spoke about how responses can change over time, how difficult-to-treat areas may respond, and what monitoring different treatments may require. His comments reflect the information he discussed in the interview, rather than broad treatment guidance. (Source: Dermatology Times Expert Perspectives interview with Mark Lebwohl, MD)
How long can it take to see the full effect?
Lebwohl said that icotrokinra and medicines called TYK2 inhibitors, which act on a pathway involved in inflammation, may continue to improve psoriasis after the first 16 weeks of treatment. People may see additional benefit through 24 weeks, with the strongest effect arriving somewhat later.
He noted that many psoriasis medicines, including oral treatments and biologics, show higher rates of complete skin clearance as people approach a year of treatment. Biologics are medicines made using living cells that target specific parts of the immune system.
One measure used in psoriasis studies is PASI 100. It means that the psoriasis affecting the skin has completely cleared according to a scoring system used in the study. Lebwohl described a reported PASI 100 rate of 54% with an oral treatment, calling it a notable result for a pill. The original interview summary does not make clear which medicine or assessment time this figure refers to. (Source: Dermatology Times Expert Perspectives interview with Mark Lebwohl, MD)
There is an important limitation to that result. The information came from an open-label extension, meaning people continued treatment while knowing which medicine they were receiving. There was no placebo group receiving an inactive treatment for comparison.
Psoriasis on the scalp, nails, hands, and feet
Psoriasis often affects the scalp, where itching can be especially troublesome. According to Lebwohl, oral psoriasis medicines generally work on the scalp as well as on other affected areas of the body.
Fingernails tend to improve more slowly than the skin. That is because the tissue beneath the nail and the area where the nail forms need to recover before a healthier-looking nail can grow out. This usually takes months.
Psoriasis on the palms and soles can also be difficult to treat. Lebwohl suggested that the larger molecules in biologic medicines may have difficulty reaching these areas through small blood vessels and the thick outer layer of skin. He described this as a possible explanation for limited responses in the hands and feet, rather than an established cause.
Oral medicines have smaller molecules. Good responses on the palms and soles have been reported largely with oral JAK inhibitors, a group of medicines that act on pathways involved in inflammation. (Source: Dermatology Times Expert Perspectives interview with Mark Lebwohl, MD)
Can the response last?
So far, Lebwohl said, the durability of response appears good. In other words, many people who respond and continue taking a medicine remain responsive during long-term follow-up.
That does not mean everyone stays on treatment or continues to benefit. Some people stop because a medicine does not help enough, while others may lose their response over time.
Why monitoring depends on the medicine
Different psoriasis treatments have different monitoring needs. Lebwohl said JAK inhibitors, which are used primarily for psoriatic arthritis in this discussion, call for blood tests and an annual tuberculosis test. Psoriatic arthritis is a condition associated with psoriasis that can cause joint pain and swelling.
The blood tests he described include a complete blood count, which checks different types of blood cells; chemistry tests, which check substances in the blood; and a lipid test, which measures blood fats such as cholesterol.
Tuberculosis, or TB, is an infection that can remain inactive in the body without causing symptoms. This is called latent TB. Some medicines can allow a latent infection to become active again.
According to Lebwohl, this can happen with TNF blockers, JAK inhibitors, methotrexate, and cyclosporine. He said IL-17 and IL-23 blockers have not been shown to reactivate latent TB, and that the U.S. Food and Drug Administration has been asked to remove the testing requirement for those medicines. IL-17, IL-23, and TNF are substances involved in immune system activity. (Source: Dermatology Times Expert Perspectives interview with Mark Lebwohl, MD)
Testing requirements can differ by medicine and individual circumstances. Treatment and monitoring decisions should be discussed with a doctor or dermatologist.
Side effects and the immune system
Yeast infections are a known side effect of IL-17 inhibitors. Lebwohl said these infections tend to be mild and often affect the tongue. A yeast infection in the mouth is called thrush, and he noted that it is usually easy to treat.
Lebwohl also said that some newer drugs have very little effect on the immune system overall. Still, medicines differ in how they work and in their possible risks.
When to speak with a doctor
If psoriasis is uncomfortable, changing, or difficult to manage, a doctor or dermatologist can help assess it. Seek medical advice for pain, bleeding, signs of infection, a rapidly growing skin change, or a lesion that is changing or causing concern.
This article is for information only and is not a substitute for medical advice. Discuss any treatment questions or decisions with a doctor or dermatologist.
Sources
- Dermatology Times Expert Perspectives custom video series: interview with Mark Lebwohl, MD, on oral psoriasis treatments, response over time, difficult-to-treat areas, durability, and monitoring.